Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1688 USD | +1.63% | -6.22% | +20.57% |
May. 20 | Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate | CI |
Feb. 15 | Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024 |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Abbreviated New Drug Applications
100.0
%
| 32 | 100.0 % | 34 | 100.0 % | +5.87% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 32 | 100.0 % | 34 | 100.0 % | +5.87% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nasrat Hakim
CEO | Chief Executive Officer | 63 | 13-07-31 |
Carter Ward
DFI | Director of Finance/CFO | 59 | 09-06-30 |
Christopher Dick
PSD | President | 69 | 02-10-31 |
Douglas Plassche
COO | Chief Operating Officer | 61 | 13-08-11 |
Dianne Will
IRC | Investor Relations Contact | - | 02-12-31 |
Kirko Kirkov
PRN | Corporate Officer/Principal | 56 | 22-09-05 |
George Smith
LAW | General Counsel | - | 14-10-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Whitnell
BRD | Director/Board Member | 68 | 09-10-22 |
Barry Dash
BRD | Director/Board Member | 93 | 05-03-31 |
Davis Caskey
BRD | Director/Board Member | 76 | 16-04-27 |
Nasrat Hakim
CEO | Chief Executive Officer | 63 | 13-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,017,881,199 | 791,526,006 ( 77.76 %) | 100,000 ( 0.009824 %) | 77.76 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+18.64% | 177M | |
+15.74% | 42.79B | |
+22.20% | 22.81B | |
+15.56% | 15.04B | |
+17.64% | 14.49B | |
+50.91% | 12.65B | |
-11.45% | 6.74B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.55% | 5.47B |
- Stock Market
- Equities
- ELTP Stock
- Company Elite Pharmaceuticals, Inc.